

# Rituximab for Serious Aplastic Anemia With Platelet Transfusion Refractoriness

NCT06254560

---

<b>Status</b>	RECRUITING
<b>Phase</b>	Phase 2
<b>Sponsor</b>	Institute of Hematology & Blood Diseases Hospital, China
<b>Enrollment</b>	20 participants

## Key Eligibility Criteria

---

### Inclusion (4)

- Initial diagnosed SAA with PTR
- Age > 18 years old, regardless of gender
- Initial diagnosed SAA with PTR
- Age > 18 years old, regardless of gender

### Exclusion (8)

- Allergy to rituximab
- Severe active infection
- Hypogammaglobulinemia
- Pregnant and lactating women
- Heart failure (NYHA classification IV)
- ... and 3 more (see full listing online)

## Locations (1 total)

---

Institute of Hematology & Blood Diseases Hospital Chinese Academy of Medical Sciences, Tianjin, Tianjin Municipality, China